LIVIVO - Search results -

Search results

Result 1 - 10 of total 30

Search options

Article ; Online: Drug-induced radiation recall reactions and non-anticancer drugs: A descriptive analysis from VigiBase®.

Aubin-Beale, Eyrian / Giorgi, Lorene / Beurrier, Mathilde / Granel-Brocard, Florence / Gillet, Pierre / Fresse, Audrey

2023 Volume 37, Issue 3, Page(s) 673–679

Abstract: Radiation recall reactions are inflammatory reactions confined to previously irradiated tissues, often of drug-induced etiology, particularly with anticancer therapies. Other drugs, in particular COVID-19 vaccines, may also be involved. To describe ... ...

Abstract	Radiation recall reactions are inflammatory reactions confined to previously irradiated tissues, often of drug-induced etiology, particularly with anticancer therapies. Other drugs, in particular COVID-19 vaccines, may also be involved. To describe radiation recall reactions under non-anticancer drugs more precisely, we extracted the cases of radiation recall reactions associated with non-anticancer drugs from WHO pharmacovigilance database VigiBase®. We performed two analyses from this extraction: a global analysis and an analysis focusing on vaccination-related issues. We extracted 120 cases corresponding to 269 drugs, of which 130 were non-anticancer (22 vaccines). Among the non-anticancer drugs, tozinameran was the most reported treatment (4.46% of cases), followed by levofloxacin (2.97%) and folinic acid (2.60%), dexamethasone (2.23), and ChAdOx1 nCoV-19 vaccine and prednisone (1.86% each). Among vaccines, tozinameran (54.55% of cases) was the most reported, followed by ChAdOx1 nCoV-19 (22.73%), HPV and inactivated influenza vaccine (9.09% each), and elasomeran (4.55%). Our study first describes the occurrence of radiation recall reactions during non-anticancer treatment. It also highlights a potential safety signal with COVID-19 vaccines.
MeSH term(s)	Humans ; COVID-19 Vaccines ; ChAdOx1 nCoV-19 ; COVID-19/epidemiology ; COVID-19/prevention & control ; BNT162 Vaccine ; Radiodermatitis ; Influenza Vaccines
Chemical Substances	COVID-19 Vaccines ; ChAdOx1 nCoV-19 (B5S3K2V0G8) ; BNT162 Vaccine ; Influenza Vaccines
Language	English
Publishing date	2023-01-11
Publishing country	England
Document type	Journal Article
ZDB-ID	639134-5
ISSN	1472-8206 ; 0767-3981
ISSN (online)	1472-8206
ISSN	0767-3981
DOI	10.1111/fcp.12866
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2247: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Does Preventive Negative Pressure Wound Therapy (NPWT) reduce local complications following Lymph Node Dissection (LND) in the management of metastatic skin tumors?

Poirier, Antoine / Albuisson, Eliane / Bihain, Florence / Granel-Brocard, Florence / Perez, Manuela

Journal of plastic, reconstructive & aesthetic surgery : JPRAS

2022 Volume 75, Issue 12, Page(s) 4403–4409

Abstract: Introduction: Axillary and inguinal lymph node dissection (LND) are performed in metastatic skin tumors with several local complications, such as lymphorrhea, lymphoceles, and lymphedema. The purpose of this study is to determine whether negative ... ...

Abstract	Introduction: Axillary and inguinal lymph node dissection (LND) are performed in metastatic skin tumors with several local complications, such as lymphorrhea, lymphoceles, and lymphedema. The purpose of this study is to determine whether negative pressure wound therapy (NPWT) applied as a preventive measure could improve outcomes. Materials and methods: A monocentric study included patients who underwent axillary or inguinal LND from May 2010 to March 2020, with a retrospective evaluation of prospectively collected data. Patients were divided into two groups: the conventional wound care (CWC) and the NPWT groups. Patients were systematically reviewed at D7, D30, and at 1 year postoperative, and data regarding lymphorrhea, lymphoceles, and lymphedema were collected. Results: A total of 109 axillary and inguinal LND were performed. NPWT was applied on 68 LND and CWC on 41 LND. The variables, diabetes, smoking, gender, associated treatments, and primary pathology (melanoma, squamous cell carcinoma, or Merkel tumors) were similar in both groups. Analyses have shown a significant difference in the rate of scar disunion during the first month between the two groups (p=0.045 between D1 and D7; p=0.011 between D8 and D30), as well as the presence of lymphorrhea (p=0.000 between D1 and D7; p=0.002 between D8 and D30). The rate of lymphoedema was significantly reduced in the NPWT group versus CWC (p=0.000 between D8 and D30; p=0.034 between D31 and 1 year). Conclusion: NPWT reduces local complications (scar disunion, lymphorrhea, and lymphedema) during the first year following LND in the management of node metastatic skin tumors.
MeSH term(s)	Humans ; Lymphocele/etiology ; Negative-Pressure Wound Therapy ; Retrospective Studies ; Cicatrix/complications ; Lymph Node Excision/adverse effects ; Skin Neoplasms/surgery ; Lymphedema/prevention & control ; Lymphedema/complications ; Lymphatic Diseases ; Lymph Nodes
Language	English
Publishing date	2022-08-24
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2217750-4
ISSN	1878-0539 ; 1748-6815 ; 0007-1226
ISSN (online)	1878-0539
ISSN	1748-6815 ; 0007-1226
DOI	10.1016/j.bjps.2022.08.054
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uk I Zs.157: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A flare-up of rheumatoid arthritis followed by adrenocorticotropic insufficiency induced by pembrolizumab: A case-report.

Garon-Czmil, Julie / Abs, Diane / Granel-Brocard, Florence / Gillet, Pierre / Yelehe-Okouma, Mélissa

Therapie

2020 Volume 76, Issue 5, Page(s) 510–512

MeSH term(s)	Antibodies, Monoclonal, Humanized/adverse effects ; Arthritis, Rheumatoid/drug therapy ; Humans
Chemical Substances	Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P)
Language	English
Publishing date	2020-11-24
Publishing country	France
Document type	Case Reports ; Letter
ZDB-ID	603474-3
ISSN	1958-5578 ; 0040-5957
ISSN (online)	1958-5578
ISSN	0040-5957
DOI	10.1016/j.therap.2020.11.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.272: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.

Geoffrois, Lionnel / Harlé, Alexandre / Sahki, Nassim / Sikanja, Aleksandra / Granel-Brocard, Florence / Hervieu, Alice / Mortier, Laurent / Jeudy, Géraldine / Michel, Catherine / Nardin, Charlée / Huin-Schohn, Cécile / Merlin, Jean-Louis

BMC cancer

2023 Volume 23, Issue 1, Page(s) 554

Abstract: Background: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) ... ...

Abstract	Background: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at one year is approximately 30% and justify extensive research of predictive biomarkers. If in metastatic disease, the follow-up of circulating tumor DNA (ctDNA) has been demonstrated, its interest in adjuvant setting remains to be precised, especially because of a lower detection rate. Further, the definition of a molecular response could prove useful to personalized treatment. Methods: PERCIMEL is an open prospective multicentric study executed through collaboration of the Institut de Cancérologie de Lorraine (non-profit comprehensive cancer center) and 6 French university and community hospitals. A total of 165 patients with resected stage III and IV melanoma, eligible to adjuvant imunotherapy or anti-BRAF/MEK kinase inhibitors will be included. The primary endpoint is the presence of ctDNA, 2 to 3 weeks after surgery, defined as mutated ctDNA copy number calculated as the allelic fraction of a clonal mutation relative to total ctDNA. Secondary endpoints are recurrence-free survival, distant metastasis-free survival and specific survival. We will follow ctDNA along treatment, quantitatively through ctDNA mutated copy number variation, qualitatively through the presence of cfDNA and its clonal evolution. Relative and absolute variations of ctDNA during follow-up will be also analyzed. PERCIMEL study aims at provide scientific evidence that ctDNA quantitative and qualitative variations can be used to predict the recurrence of patients with melanoma treated with adjuvant immunotherapy or kinase inhibitors, thus defining the notion of molecular recurrence.
MeSH term(s)	Humans ; Melanoma/genetics ; Melanoma/therapy ; Melanoma/pathology ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Prospective Studies ; Cell-Free Nucleic Acids ; Follow-Up Studies ; DNA Copy Number Variations ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Mutation ; Melanoma, Cutaneous Malignant
Chemical Substances	Cell-Free Nucleic Acids ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
Language	English
Publishing date	2023-06-16
Publishing country	England
Document type	Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-023-11029-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Sweet syndrome and erythema nodosum in a case of anal canal cancer during concomitant radiochemotherapy.

Moreau, Estelle / Peiffert, Didier / Schmutz, Jean Luc / Granel-Brocard, Florence / Bursztejn, Anne-Claire

European journal of dermatology : EJD

2019 Volume 29, Issue 5, Page(s) 539–540

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Anus Neoplasms/therapy ; Chemoradiotherapy/adverse effects ; Erythema Nodosum/diagnosis ; Erythema Nodosum/etiology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Middle Aged ; Mitomycin/administration & dosage ; Mitomycin/adverse effects ; Sweet Syndrome/diagnosis ; Sweet Syndrome/etiology
Chemical Substances	Mitomycin (50SG953SK6) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2019-10-16
Publishing country	France
Document type	Case Reports ; Journal Article
ZDB-ID	1128666-0
ISSN	1952-4013 ; 1167-1122
ISSN (online)	1952-4013
ISSN	1167-1122
DOI	10.1684/ejd.2019.3628
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3484: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab.

Escobar, Gabriela Fortes / Granel-Brocard, Florence / Schmutz, Jean-Luc / Cervantes, Pierre / Ben Mahmoud, Sinan / Bursztejn, Anne-Claire

Dermatologic therapy

2020 Volume 33, Issue 6, Page(s) e13951

MeSH term(s)	Antibodies, Monoclonal, Humanized ; Carcinoma, Squamous Cell ; Humans ; Lung ; Skin Neoplasms
Chemical Substances	Antibodies, Monoclonal, Humanized ; cemiplimab (6QVL057INT)
Language	English
Publishing date	2020-07-16
Publishing country	United States
Document type	Letter
ZDB-ID	1354801-3
ISSN	1529-8019 ; 1396-0296
ISSN (online)	1529-8019
ISSN	1396-0296
DOI	10.1111/dth.13951
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Colite ulcérée sévère lors d’un traitement par ipilimumab sans récidive après cure d’infliximab et relai secondaire par pembrolizumab.

Yelehe-Okouma, Mélissa / Granel-Brocard, Florence / Hudziak, Hervé / Schmutz, Jean-Luc / Gillet, Pierre

Therapie

2017 Volume 73, Issue 3, Page(s) 291–293

Title translation	Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab.
MeSH term(s)	Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Colitis, Ulcerative/chemically induced ; Colitis, Ulcerative/diagnostic imaging ; Colitis, Ulcerative/drug therapy ; Crohn Disease/chemically induced ; Crohn Disease/diagnostic imaging ; Humans ; Infliximab/adverse effects ; Infliximab/therapeutic use ; Ipilimumab/adverse effects ; Ipilimumab/therapeutic use ; Male ; Melanoma/complications ; Melanoma/drug therapy
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; Ipilimumab ; Infliximab (B72HH48FLU) ; pembrolizumab (DPT0O3T46P)
Language	French
Publishing date	2017-11-16
Publishing country	France
Document type	Case Reports ; Letter
ZDB-ID	603474-3
ISSN	1958-5578 ; 0040-5957
ISSN (online)	1958-5578
ISSN	0040-5957
DOI	10.1016/j.therap.2017.10.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.272: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Apport du panel multiparamétrique CD3 CD4 CD8 CD7 CD26 CD158k dans la détection et le suivi par cytométrie en flux des cellules de Sézary.

Callet, Jonas / Latger-Cannard, Véronique / Gérard, Delphine / Salignac, Sylvain / Granel-Brocard, Florence / Campidelli, Arnaud / Bursztejn, Anne-Claire / Broséus, Julien / Vial, Jean-Philippe / Lesesve, Jean-François

Annales de biologie clinique

2021 Volume 79, Issue 3, Page(s) 233–240

Abstract: The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × ... ...

Title translation	Use of the multiparametric panel CD3/CD4/CD8/CD7/CD26/CD158k in the detection and use of flow cytometry of Sezary cells.
Abstract	The Sezary syndrome has been defined by a triad combining erythrodermia, generalized lymphadenopathy, and the presence of circulating Sezary cells > 1 × 10
MeSH term(s)	Antigens, CD ; Biomarkers, Tumor ; CD8-Positive T-Lymphocytes ; Dipeptidyl Peptidase 4 ; Flow Cytometry ; Humans ; Retrospective Studies ; Skin Neoplasms/diagnosis
Chemical Substances	Antigens, CD ; Biomarkers, Tumor ; Dipeptidyl Peptidase 4 (EC 3.4.14.5)
Language	French
Publishing date	2021-06-24
Publishing country	France
Document type	Journal Article
ZDB-ID	418098-7
ISSN	1950-6112 ; 0003-3898
ISSN (online)	1950-6112
ISSN	0003-3898
DOI	10.1684/abc.2021.1651
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.203: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.

Annals of the rheumatic diseases

2022 Volume 81, Issue 10, Page(s) 1445–1452

Abstract: Objective: To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma.: Methods: Case-control study performed on a ... ...

Abstract	Objective: To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma. Methods: Case-control study performed on a French multicentric prospective cohort of patients with melanoma, matched for irAE risk factors and oncological staging. Risk of irAE was assessed by logistic regression. Results: 110 patients with pAID were included and matched with 330 controls, from March 2013 to October 2020. Over a median follow-up period of 7.2 months for cases and 6.9 months for controls, the ORs of developing all-grade and grade ≥3 irAEs among cases compared with controls were 1.91 (95% CI (1.56 to 2.27)) and 1.44 (95% CI (1.08 to 1.82)), respectively. Patients with pAID had an increased risk of multiple irAEs (OR 1.46, 95% CI (1.15 to 2.67)) and a shorter time to irAE onset. In contrast, there were no difference in irAE-related mortality nor in the rate of treatment discontinuation, and a landmark analysis revealed a better survival at 24 months among cases (p=0.02). Thirty per cent of cases experienced a pAID flare during follow-up, and baseline immunosuppression did not prevent irAE occurrence. Last, we report associations between the pAID clinical subsets and organ-specific irAEs. Conclusion: In our study, patients with pAID were at greater risk of all-grade, severe and multiple irAEs, yet had a better 24-month survival than controls. Thus, patients with pAID should be eligible for ICI therapy but benefit from a close monitoring for irAE occurrence, especially during the first months of therapy.
MeSH term(s)	Antineoplastic Agents, Immunological/adverse effects ; Autoimmune Diseases/chemically induced ; Autoimmune Diseases/drug therapy ; Case-Control Studies ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune System Diseases ; Melanoma/drug therapy ; Prospective Studies ; Retrospective Studies
Chemical Substances	Antineoplastic Agents, Immunological ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2022-07-04
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/ard-2022-222186
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hidradénite neutrophilique eccrine associée à une leucémie aiguë myéloïde.

Bonhomme, Axelle / Liegeon, Anne-Laure / Granel-Brocard, Florence / Barbaud, Annick / Schmutz, Jean-Luc

Presse medicale (Paris, France : 1983)

2015 Volume 44, Issue 6 Pt 1, Page(s) 688–689

Title translation	Neutrophilic eccrine hidradenitis associated with acute myeloid leukemia.
MeSH term(s)	Female ; Hidradenitis/etiology ; Humans ; Leukemia, Myeloid, Acute/complications ; Middle Aged
Language	French
Publishing date	2015-06
Publishing country	France
Document type	Case Reports ; Letter
ZDB-ID	120943-7
ISSN	2213-0276 ; 0032-7867 ; 0755-4982 ; 0301-1518
ISSN (online)	2213-0276
ISSN	0032-7867 ; 0755-4982 ; 0301-1518
DOI	10.1016/j.lpm.2015.02.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 794: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Ua VI Zs.87: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito